The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis
Open accessAbstract
Background: Although clozapine is the ‘gold standard’ for treatment-refractory schizophrenia, meta-analyses of clozapine for this condition are lacking. Aims: We conducted a systematic review and meta-analysis of clozapine treatment for people with treatment-refractory schizophrenia. Method: We searched the Cochrane Schizophrenia Group's trial register, PubMed and EMBASE and hand-searched key papers for randomised controlled trials of clozapine for treatment-refractory schizophrenia. Results: Twenty-one papers with 25 comparisons were included. The number needed to treat was 9. Clozapine was superior for positive symptoms in both the short and long term. In the short term only clozapine was superior for total and negative symptoms, with higher response rates. Both funding source and dosage affected results. Higher baseline psychosis scores predicted better outcomes for clozapine in a meta-regression. Conclusions: Clozapine is superior for treatment-refractory disorder but if there is no response by 6 months medications with lower adverse reactions should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,701
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Scale for Assessment of Positive Symptoms (SAPS) 1984
Andreasen, N. C. (1995) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 2,423
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Scale for the Assessment of Negative Symptoms
Andreasen, N. C. (2014) · PsycTESTS Dataset · doi:10.1037/t12696-000 · Cited by 1,866
The nuts and bolts of PROSPERO: an international prospective register of systematic reviews
Booth, A., Clarke, M., Dooley, G., Ghersi, D., Moher, D., Petticrew, M., & Stewart, L. (2012) · Systematic Reviews · doi:10.1186/2046-4053-1-2 · Cited by 1,433
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D., & Ho, B.-C. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.040 · Cited by 943
The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements
Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., Goldberg, R. W., Lehman, A., Tenhula, W. N., Calmes, C., Pasillas, R. M., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp115 · Cited by 774
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.45859 · Cited by 737
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For The Treatment Of Schizophrenia And Related Disorders (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01516.x · Cited by 435
Childhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830120020005 · Cited by 410
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 357
Howes, O. D., Vergunst, F., Gee, S., McGuire, P., Kapur, S., & Taylor, D. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.105833 · Cited by 353
Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method
Leucht, S., Samara, M., Heres, S., Patel, M. X., Furukawa, T., Cipriani, A., Geddes, J., & Davis, J. M. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv037 · Cited by 318
Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B., & Baumann, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.499 · Cited by 283
Buchanan, R. W., Breier, A., Kirkpatrick, B., Ball, P., & Carpenter, W. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.751 · Cited by 264
Citrome, L., & Ketter, T. A. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12142 · Cited by 250
Agranulocytosis during treatment with clozapine
Id�np��n-Heikkil�, J., Alhava, E., Olkinuora, M., & Palva, I. P. (1977) · European Journal of Clinical Pharmacology · doi:10.1007/bf00606409 · Cited by 237
Clozapine: a review of clinical practice guidelines and prescribing trends
Warnez, S., & Alessi-Severini, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-102 · Cited by 234
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225
Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Kafantaris, V., Correll, C. U., & Kane, J. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.043 · Cited by 223
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.
Potkin, S. G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., Richmond, G., Carreon, D., Sitanggan, K., & Gerber, B. (1994) · PubMed · Cited by 206
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202
Azorin, J.-M., Spiegel, R., Remington, G., Vanelle, J.-M., Péré, J.-J., Giguere, M., & Bourdeix, I. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1305 · Cited by 179
Kane, J. M., Marder, S. R., Schooler, N. R., Wirshing, W. C., Umbricht, D., Baker, R. W., Wirshing, D. A., Safferman, A., Ganguli, R., McMeniman, M., et al. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.965 · Cited by 178
Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, K., Aygun, C., Elif, E. A., Yagcioglu, A., & Small, J. G. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0214 · Cited by 176
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147
Equipercentile linking of the BPRS and the PANSS
Leucht, S., Rothe, P., Davis, J. M., & Engel, R. R. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.11.004 · Cited by 126
Naber, D., Riedel, M. J., Klimke, A., Vorbach, E.-U., Lambert, M., Kühn, K. ‐., Bender, S., Bandelow, B., Lemmer, W., Moritz, S., et al. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00486.x · Cited by 102
A review of the use of clozapine levels to guide treatment and determine cause of death
Stark, A., & Scott, J. G. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412438871 · Cited by 94
Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study
Wahlbeck, K., Cheine, M. V., Tuisku, K., Ahokas, A., Joffe, G., & Rimón, R. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00118-4 · Cited by 76
Moncrieff, J. (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.183.2.161 · Cited by 74
Sacchetti, E., Galluzzo, A., Valsecchi, P., Romeo, F., Gorini, B., & Warrington, L. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.017 · Cited by 66
Hong, C.-J., Chen, J., Chiu, H.-J., & Sim, C. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00001 · Cited by 61
Increasing Clozapine Dispensing Trends in Queensland, Australia 2004–2013
Forrester, T., Siskind, D. J., Winckel, K., Wheeler, A., & Hollingworth, S. (2015) · Pharmacopsychiatry · doi:10.1055/s-0035-1554713 · Cited by 46
Self-citationMoresco, R. M., Cavallaro, R., Messa, C., Bravi, D., Gobbo, C. L., Galli, L., Lucignani, G., Colombo, C., Rizzo, G., Velonà, I., et al. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800306 · Cited by 46
Cited by
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Self-citationJauhar, S., Johnstone, M., & McKenna, P. J. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01730-x · Cited by 996
Machine Learning Approaches for Clinical Psychology and Psychiatry
Dwyer, D. B., Falkai, P., & Koutsouleris, N. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045037 · Cited by 966
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Siskind, D., Siskind, V., & Kisely, S. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717718167 · Cited by 391
Self-citation
Metadata
- Authors
- Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2016-11
- Volume
- 209
- Issue
- 5
- Pages
- 385-392
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2461169273
- Cited by
- 601
- References
- 47
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.